Literature DB >> 17709299

Breast cancer follow-up: literature review and discussion.

Carmel Sheppard1.   

Abstract

This paper presents a review of the evidence for long-term breast cancer follow up to determine if routine clinical review post treatment for breast cancer has benefits for patients. There is little evidence that clinical review of patients beyond 3 years post-diagnosis leads to improved patient survival. Separate to survival there is a dearth of inquiry relating to the value of long-term clinical review of patient in terms of psychological outcomes, quality of life, patient satisfaction, access to specialist advice regarding management of symptoms, and reassurance. Regardless of supporting evidence, most breast units in the UK continue to undertake routine six monthly clinical reviews of patients up to a minimum of 5 years. A literature search for the period 1989 to January 2006 was undertaken using the CINAHL, MEDLINE, and PsychINFO databases. Keywords such as 'cancer follow-up', 'cancer survivorship', and 'psychological outcomes of cancer' were utilised. Hand searching was also undertaken. Overall a paucity of evidence was found in relation to the long-term needs of breast cancer survivors. Alternatives to hospital-based follow-up are reported such as GP or nurse-led follow-up, but the fundamental question of the importance of follow-up in relation to psychological morbidity and quality of life still remains unanswered. Further research is needed to investigate the importance of follow-up to patient survivorship. Research to explore the concept of point of need access, as well as the qualitative experiences of patients post-discharge, informational needs at discharge and on-going psychosocial support is suggested. Ultimately this paper argues for a greater choice and involvement of patients in determining their future follow up needs, providing the patient with a personalised package of care based on risk assessment and subsequent education programmes to empower patients towards self-management following discharge.

Entities:  

Mesh:

Year:  2007        PMID: 17709299     DOI: 10.1016/j.ejon.2006.09.001

Source DB:  PubMed          Journal:  Eur J Oncol Nurs        ISSN: 1462-3889            Impact factor:   2.398


  7 in total

1.  Adaptation of the illness trajectory framework to describe the work of transitional cancer survivorship.

Authors:  Rachel Klimmek; Jennifer Wenzel
Journal:  Oncol Nurs Forum       Date:  2012-11       Impact factor: 2.172

2.  Follow-up care in cancer: adjusting for referral targets and extending choice.

Authors:  Kate Wilson; Anne Lydon; Ziv Amir
Journal:  Health Expect       Date:  2011-05-25       Impact factor: 3.377

3.  Marital status and optimism score among breast cancer survivors.

Authors:  Lindsay Croft; John Sorkin; Lisa Gallicchio
Journal:  Support Care Cancer       Date:  2014-06-08       Impact factor: 3.603

4.  Geographical comparisons of information and support needs of Australian women following the primary treatment of breast cancer: a 10-year replication study.

Authors:  Tracey Ahern; Anne Gardner; Mary Courtney
Journal:  Health Expect       Date:  2014-07-29       Impact factor: 3.377

5.  Problems in transition and quality of care: perspectives of breast cancer survivors.

Authors:  Aimee Kendall Roundtree; Sharon H Giordano; Andrea Price; Maria E Suarez-Almazor
Journal:  Support Care Cancer       Date:  2010-12-09       Impact factor: 3.603

6.  Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments.

Authors:  Rana El Haidari; Amelie Anota; Tienhan S Dabakuyo-Yonli; Francis Guillemin; Thierry Conroy; Michel Velten; Damien Jolly; Sylvain Causeret; Jean Cuisenier; Olivier Graesslin; Linda Abou Abbas; Virginie Nerich
Journal:  Qual Life Res       Date:  2022-05-19       Impact factor: 3.440

7.  Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study.

Authors:  Kelly M de Ligt; Annemieke Witteveen; Sabine Siesling; Lotte M G Steuten
Journal:  BMC Cancer       Date:  2018-01-24       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.